Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease

Research output: Contribution to journalJournal articlepeer-review

Standard

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. / Bader, Jakob M; Geyer, Philipp E; Müller, Johannes B; Strauss, Maximilian T; Koch, Manja; Leypoldt, Frank; Koertvelyessy, Peter; Bittner, Daniel; Schipke, Carola G; Incesoy, Enise I; Peters, Oliver; Deigendesch, Nikolaus; Simons, Mikael; Jensen, Majken K; Zetterberg, Henrik; Mann, Matthias.

In: Molecular Systems Biology, Vol. 16, No. 6, e9356, 2020.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Bader, JM, Geyer, PE, Müller, JB, Strauss, MT, Koch, M, Leypoldt, F, Koertvelyessy, P, Bittner, D, Schipke, CG, Incesoy, EI, Peters, O, Deigendesch, N, Simons, M, Jensen, MK, Zetterberg, H & Mann, M 2020, 'Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease', Molecular Systems Biology, vol. 16, no. 6, e9356. https://doi.org/10.15252/msb.20199356

APA

Bader, J. M., Geyer, P. E., Müller, J. B., Strauss, M. T., Koch, M., Leypoldt, F., Koertvelyessy, P., Bittner, D., Schipke, C. G., Incesoy, E. I., Peters, O., Deigendesch, N., Simons, M., Jensen, M. K., Zetterberg, H., & Mann, M. (2020). Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Molecular Systems Biology, 16(6), [e9356]. https://doi.org/10.15252/msb.20199356

Vancouver

Bader JM, Geyer PE, Müller JB, Strauss MT, Koch M, Leypoldt F et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Molecular Systems Biology. 2020;16(6). e9356. https://doi.org/10.15252/msb.20199356

Author

Bader, Jakob M ; Geyer, Philipp E ; Müller, Johannes B ; Strauss, Maximilian T ; Koch, Manja ; Leypoldt, Frank ; Koertvelyessy, Peter ; Bittner, Daniel ; Schipke, Carola G ; Incesoy, Enise I ; Peters, Oliver ; Deigendesch, Nikolaus ; Simons, Mikael ; Jensen, Majken K ; Zetterberg, Henrik ; Mann, Matthias. / Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. In: Molecular Systems Biology. 2020 ; Vol. 16, No. 6.

Bibtex

@article{12c8d0f830814823b087596997aa6628,
title = "Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease",
abstract = "Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers for diagnosis, prognosis, and treatment efficacy. Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid (CSF). Alzheimer's disease (AD) patients have higher CSF levels of tau, but we lack knowledge of systems-wide changes of CSF protein levels that accompany AD. Here, we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts. From three independent studies (197 individuals), we characterize differences in proteins by AD status (> 1,000 proteins, CV < 20%). Proteins with previous links to neurodegeneration such as tau, SOD1, and PARK7 differed most strongly by AD status, providing strong positive controls for our approach. CSF proteome changes in Alzheimer's disease prove to be widespread and often correlated with tau concentrations. Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study. Machine learning suggests clinical utility of this proteomic signature.",
author = "Bader, {Jakob M} and Geyer, {Philipp E} and M{\"u}ller, {Johannes B} and Strauss, {Maximilian T} and Manja Koch and Frank Leypoldt and Peter Koertvelyessy and Daniel Bittner and Schipke, {Carola G} and Incesoy, {Enise I} and Oliver Peters and Nikolaus Deigendesch and Mikael Simons and Jensen, {Majken K} and Henrik Zetterberg and Matthias Mann",
note = "{\textcopyright} 2020 The Authors. Published under the terms of the CC BY 4.0 license.",
year = "2020",
doi = "10.15252/msb.20199356",
language = "English",
volume = "16",
journal = "Molecular Systems Biology",
issn = "1744-4292",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease

AU - Bader, Jakob M

AU - Geyer, Philipp E

AU - Müller, Johannes B

AU - Strauss, Maximilian T

AU - Koch, Manja

AU - Leypoldt, Frank

AU - Koertvelyessy, Peter

AU - Bittner, Daniel

AU - Schipke, Carola G

AU - Incesoy, Enise I

AU - Peters, Oliver

AU - Deigendesch, Nikolaus

AU - Simons, Mikael

AU - Jensen, Majken K

AU - Zetterberg, Henrik

AU - Mann, Matthias

N1 - © 2020 The Authors. Published under the terms of the CC BY 4.0 license.

PY - 2020

Y1 - 2020

N2 - Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers for diagnosis, prognosis, and treatment efficacy. Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid (CSF). Alzheimer's disease (AD) patients have higher CSF levels of tau, but we lack knowledge of systems-wide changes of CSF protein levels that accompany AD. Here, we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts. From three independent studies (197 individuals), we characterize differences in proteins by AD status (> 1,000 proteins, CV < 20%). Proteins with previous links to neurodegeneration such as tau, SOD1, and PARK7 differed most strongly by AD status, providing strong positive controls for our approach. CSF proteome changes in Alzheimer's disease prove to be widespread and often correlated with tau concentrations. Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study. Machine learning suggests clinical utility of this proteomic signature.

AB - Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers for diagnosis, prognosis, and treatment efficacy. Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid (CSF). Alzheimer's disease (AD) patients have higher CSF levels of tau, but we lack knowledge of systems-wide changes of CSF protein levels that accompany AD. Here, we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts. From three independent studies (197 individuals), we characterize differences in proteins by AD status (> 1,000 proteins, CV < 20%). Proteins with previous links to neurodegeneration such as tau, SOD1, and PARK7 differed most strongly by AD status, providing strong positive controls for our approach. CSF proteome changes in Alzheimer's disease prove to be widespread and often correlated with tau concentrations. Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study. Machine learning suggests clinical utility of this proteomic signature.

U2 - 10.15252/msb.20199356

DO - 10.15252/msb.20199356

M3 - Journal article

C2 - 32485097

VL - 16

JO - Molecular Systems Biology

JF - Molecular Systems Biology

SN - 1744-4292

IS - 6

M1 - e9356

ER -

ID: 243474537